INSM: TPIP sustained best-in-class efficacy and safety at 12 months, with 65% reaching low-risk status
The 12-month open-label extension of TPIP in PAH patients showed sustained and robust improvements in exercise capacity, cardiac biomarkers, and risk scores, with a favorable safety profile even at high doses. Over 25% achieved functional class 1, and 65% reached refined low-risk status, supporting…